Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer

Inclusion Criteria

• Has read, understood and signed the informed consent form (ICF) approved by the Independent Review Board/Ethics Committee (IRB/EC)
• Is between the ages of 18 and 75 years old, inclusive
• Has histologically or cytologically confirmed stage IIIB (malignant pericardial or pleural effusion) or stage IV non-small cell lung cancer
• Has measurable disease, defined as at least one tumor that fulfills the criteria for a target lesion according to RECIST
• Has an ECOG performance status of 0 or 1
• Has a life expectancy of > 3 months
• Has adequate hematologic function as evidenced by:
• ANC ≥ 1,500/μL
• PLT ≥ 100,000/μL
• HGB ≥ 9 g/dL obtained within 1 week prior to the first dose of study medication;
• Has adequate renal function as evidenced by:
• Serum creatinine ≤ 1.5 X the upper limit of normal (ULN) for the reference lab
• Urine dipstick for proteinuria of 30% of active bone marrow or any radiation therapy within 3 weeks of Day 1
• Has a known hypersensitivity to baker's yeast, or has an active yeast infection
• Has had previous exposure to Betafectin® or Imprime PGG
• Has an active infection
• Presents with any of the following medical diagnoses/conditions at the time of screening:
• Central nervous system (CNS) metastases
• Uncontrolled hypertension (>150/100 mmHg) or hypertension that requires > two agents for adequate control
• Peripheral neuropathy ≥ grade 2 from any cause
• Fever of >38.5° C within 3 days prior to screening or Day 1, initial dosing
• Known HIV/AIDs, Hepatitis B, Hepatitis C, connective tissue or autoimmune disease, or other clinical diagnosis, ongoing or intercurrent illness that in the physician's opinion could interfere with participation
• Has a history of any of the following medical diagnoses/conditions:
• Myocardial infarction or an unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable angina, congestive heart failure) within the previous 6 months
• Second malignancy within the previous 5 years, other than basal cell carcinoma, cervical intra-epithelial neoplasia or curatively treated prostate cancer with a PSA of <2.0 ng/mL
• Has a known hypersensitivity to cetuximab, murine proteins, or any component of cetuximab
• Has a know sensitivity to Cremophor EL
• Has previously received treatment with cetuximab
• If female, is pregnant or breast-feeding
• Is receiving concurrent investigational therapy or has received investigational therapy within a period of 30 days prior to the first scheduled day of dosing (investigational therapy is defined as treatment for which there is currently no regulatory-authority-approved indication)
• Has previously received an organ or progenitor/stem cell transplant.